InoCardia: Human Traberculae Work-Loop Feasibility

InoCardia：人类小梁工作循环可行性

• 批准号: 131722
• 金额: $ 26.28万
• 依托单位: INOCARDIA LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131722
• 关键词: InoCardia; Human; Traberculae; Work; Loop

When drugs are developed to treat a particular disease they sometimes have side effects that cause damage to to the heart. Occasionally these dangerous side effects are only recognised after the drug has been marketed and thousands of patients have been treated. This is a significant risk to human health and causes very high costs to the pharmaceutical industry when a potentially dangerous product is withdrawn from market. Although side effects of drugs can be caused by many things, one area of great concern is the effects of drugs on the force that that heart muscle can produce during its role in pumping blood around the body. Current drug testing relies mainly on the use of animals, often via tissue taken from animals, such that the tests do not do well in predicting the effect on humans. Therefore, we need to develop a test that uses human heart muscle tissue in a way that can efficiently test many drugs to reduce the risk of any approved drugs causing damage to the heart.

当药物被开发用于治疗一种特殊疾病时，它们有时会产生对心脏造成损害的副作用。有时，这些危险的副作用只有在药物上市和成千上万的患者接受治疗后才被认识到。这是对人类健康的重大风险，当一种潜在危险的产品从市场上撤出时，会给制药业造成非常高的成本。虽然药物的副作用可能由许多因素引起，但一个值得关注的领域是药物对心脏肌肉在向全身泵血时产生的力量的影响。目前的药物测试主要依赖于使用动物，通常是通过从动物身上提取的组织，因此测试不能很好地预测对人类的影响。因此，我们需要开发一种使用人体心肌组织的测试方法，这种方法可以有效地测试许多药物，以降低任何批准的药物对心脏造成损害的风险。